Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-005
- Development stage
- Preclinical
- Lead developer
- Mentari Therapeutics
01
Overview
MT-005 is a preclinical-stage biologic candidate being developed by Mentari Therapeutics for the prevention of migraine. Discovered by Paragon Therapeutics, the program targets an undisclosed novel pathway in migraine pathophysiology. MT-005 is currently in the discovery phase, with development candidate selection anticipated in the first half of 2027.
Beyond the preview
Go deeper on MT-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-005.